TY - JOUR
T1 - Complications of the MANTA Closure Device
T2 - Insights From MAUDE Database
AU - Megaly, Michael
AU - Sedhom, Ramy
AU - Abdelmaseeh, Peter
AU - ElBebawy, Bishoy
AU - Goel, Sachin S.
AU - Karam, Joseph
AU - Pershad, Ashish
AU - Brilakis, Emmanouil S.
AU - Garcia, Santiago
N1 - Publisher Copyright:
© 2021 Elsevier Inc.
PY - 2022/1
Y1 - 2022/1
N2 - Background: The collagen-based MANTA device (Teleflex, PA, USA) is used for closure of large-bore vascular access. There is a paucity of data on complications associated with its use in a real-life setting. Methods: We queried the “Manufacturer and User Facility Device Experience” MAUDE database between February 2019 and December 2020 for reports on MANTA device. Results: We identified 250 reports in the MAUDE database from February 2019 through December 2020. The most common failure complication of MANTA is persistent bleeding (48.8%) and vessel occlusion or stenosis (29.6%). Most complications were managed successfully with an endovascular approach (48.4%), but a high number of patients required surgical intervention (40.4%). The most commonly reported failure mechanism was the failure of deployment (22%) followed by subcutaneous deployment (7.6%), intraluminal deployment (4.8%) amd detachment of collagen (2.8%). Access site infection was rare (1.2%). The 18 Fr. MANTA was associated with a lower risk of failure of deployment compared with the 14 Fr. device but was associated with a higher risk of vessel occlusion or stenosis (32.4% vs. 16.3%, p = 0.04) and thrombosis (11.6% vs 0%, p = 0.03). Conclusions: The most common complication of the MANTA device reported to the MAUDE registry was persistent bleeding (48.8% of reports) followed by vessel occlusion (29.6%). These complications were managed successfully using an endovascular approach in 48.4% of the reports.
AB - Background: The collagen-based MANTA device (Teleflex, PA, USA) is used for closure of large-bore vascular access. There is a paucity of data on complications associated with its use in a real-life setting. Methods: We queried the “Manufacturer and User Facility Device Experience” MAUDE database between February 2019 and December 2020 for reports on MANTA device. Results: We identified 250 reports in the MAUDE database from February 2019 through December 2020. The most common failure complication of MANTA is persistent bleeding (48.8%) and vessel occlusion or stenosis (29.6%). Most complications were managed successfully with an endovascular approach (48.4%), but a high number of patients required surgical intervention (40.4%). The most commonly reported failure mechanism was the failure of deployment (22%) followed by subcutaneous deployment (7.6%), intraluminal deployment (4.8%) amd detachment of collagen (2.8%). Access site infection was rare (1.2%). The 18 Fr. MANTA was associated with a lower risk of failure of deployment compared with the 14 Fr. device but was associated with a higher risk of vessel occlusion or stenosis (32.4% vs. 16.3%, p = 0.04) and thrombosis (11.6% vs 0%, p = 0.03). Conclusions: The most common complication of the MANTA device reported to the MAUDE registry was persistent bleeding (48.8% of reports) followed by vessel occlusion (29.6%). These complications were managed successfully using an endovascular approach in 48.4% of the reports.
KW - Complications
KW - Large-bore access
KW - MANTA
KW - Vascular closure devices
KW - Hemostatic Techniques/adverse effects
KW - Humans
KW - Treatment Outcome
KW - Catheterization, Peripheral
KW - Femoral Artery/surgery
KW - Vascular Closure Devices
UR - http://www.scopus.com/inward/record.url?scp=85101061022&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85101061022&partnerID=8YFLogxK
U2 - 10.1016/j.carrev.2021.02.013
DO - 10.1016/j.carrev.2021.02.013
M3 - Article
C2 - 33612411
AN - SCOPUS:85101061022
SN - 1553-8389
VL - 34
SP - 75
EP - 79
JO - Cardiovascular Revascularization Medicine
JF - Cardiovascular Revascularization Medicine
ER -